CA-SONY-INTERACTIVE
8.9.2021 16:02:09 CEST | Business Wire | Press release
Sony Interactive Entertainment (“SIE”) announced today that SIE has entered into a definitive agreement to acquire Firesprite Limited, the UK-based videogame studio with a history of developing highly-polished showpieces for cutting-edge hardware. With a partnership spanning more than 8 years and a games portfolio highlighting PlayStation’s technological innovations, Firesprite will play a critical role in strengthening SIE’s exclusive games catalog in genres outside of PlayStation Studios’ core offerings.
Founded by industry veterans from SIE’s Studio Liverpool, Firesprite has a strong record of developing showcase games for PlayStation console and peripheral launches. Over the past few years, Firesprite has partnered with SIE to develop games for the PlayStation®4 and PlayStation®VR launch including The Playroom (PS4) and The Playroom VR (PS VR), both of which showcased unique hardware capabilities with highly-quality gameplay.
Originally a PS VR exclusive, with its most recent release, The Persistence , Firesprite pushed the boundaries of how users interact with the PS VR headset by introducing a groundbreaking virtual reality social element that further demonstrated the studio’s technical and creative capabilities. Later adapted for flat screens in 2018, Firesprite recently released The Persistence Enhanced in June 2021 which optimized the game for PlayStation®5 to include DualSense™ wireless controller haptic feedback, adaptive triggers, and raytraced rendering.
“We are delighted to welcome Firesprite into the PlayStation family,” said Jim Ryan, President & CEO, Sony Interactive Entertainment. “We have a rich history of working with the founders of Firesprite and are excited to grow the PlayStation presence in Liverpool. The portfolio of titles Firesprite has developed has continually demonstrated the team’s ability to transcend traditional gameplay experiences and brilliantly showcase the potential of our hardware.”
“Creating quality, state-of-the-art games has always been at the forefront of Firesprite’s work and I’m confident they will push the bar even further as part of PlayStation Studios,” said Hermen Hulst, Head of PlayStation Studios. “Firesprite’s ability to weave best-in-class gameplay with new technology is exceptional and I think fans will be excited about their creative vision for the future.”
“At Firesprite, we’re always striving to bring something new to a game or genre and developing for new technologies is a driving force of our passion,” said Graeme Ankers, Managing Director, Firesprite. “Joining PlayStation Studios will allow us to amplify this passion, working more closely on cutting-edge hardware without any limitations and furthering our studio’s heritage of creativity and technical innovation to offer some truly unique experiences for PlayStation fans.”
Based in Liverpool, UK Firesprite will join the global development operation of PlayStation Studios and will be the 14th studio to join the PlayStation Studios family. The day-to-day operations post-acquisition will continue to be run by Firesprite’s current management team. Terms of this transaction including the acquisition cost are not disclosed due to contractual commitments.
About Sony Interactive Entertainment
Recognized as a global leader in interactive and digital entertainment, Sony Interactive Entertainment (SIE) is responsible for the PlayStation® brand and family of products and services. PlayStation has delivered innovation to the market since the launch of the original PlayStation in Japan in 1994. The PlayStation family of products and services include PlayStation®5, PlayStation®4, PlayStation®VR, PlayStation™Store, PlayStation®Plus, PlayStation™Now, and acclaimed PlayStation software titles from PlayStation Studios. Headquartered in San Mateo, California, SIE is a wholly owned subsidiary of Sony Group Corporation and has global functions in California, London and Tokyo.
About Firesprite
Founded in 2012 by a group of creative and management veterans with years of industry experience, Firesprite is a visionary game development studio based in the heart of Liverpool’s vibrant game development hub with over 200 team members. Creating a number of showcase games for PlayStation console and peripheral launches over the years, Firesprite’s core focus is developing innovative and memorable experiences for players on cutting edge gaming hardware. At Firesprite, the end player experience always comes first and the team is passionate about how to best combine the disciplines of design, art and code to deliver experiences that surprise and delight.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom